Key Kidney Cancer Data at ASCO GU 2019

Sumanta Kumar Pal | March 04, 2019

San Francisco has been hopping since the start of the new year, with multiple meetings causing tidal waves of change in oncology. The J.P. Morgan meeting was the first of these, showcasing multiple mergers and acquisitions in biotech and hinting towards major development efforts in CAR-T and BiTE technologies. ASCO GU came next, with stunning data for combinations of immune and targeted therapy in challenging diseases such as esophageal and gastric cancer.

READ MORE PREVIOUS ARTICLES

Sumanta Kumar Pal, MD

Sumanta (Monty) Kumar Pal, MD, is an internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is the Co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease. Dr. Pal sits on the Editorial Board for clinical genitourinary cancer and is a reviewer for multiple journals including The Journal of Clinical Oncology, The Journal of Urology, European Urology, and many others.

Beyond the Abstracts
Author insights on peer reviewed manuscripts
Conference Coverage
Recent data from conferences worldwide

EAU 2019 Kidney Cancer

ASCO GU 2019 Kidney Cancer

ESOU 2019 Kidney Cancer

CUOS 2019 Kidney Cancer

SUO 2018 Kidney Cancer

ESMO 2018 Kidney Cancer

AUA 2018 Northeastern Section

FOIU 2018 Kidney Cancer

ASCO 2018 Renal Cancer

AUA 2018 Renal Cancer

EAU 2018 Kidney Cancer

ASCO GU 2018 Renal Cancer

ESMO 2017 Kidney Cancer

ASCO 2017 Renal Cancer

ASCO GU 2017 Kidney Cancer

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe